Description: Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Genera and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine and Food producing Animal Products. It includes third party manufacturing and other non-core activities sales. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal and Equine Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos and Vetoryl.
Home Page: www.dechra.com
DPH Technical Analysis
24 Cheshire Avenue
Northwich,
CW9 7UA
United Kingdom
Phone:
44 1606 814730
Officers
| Name | Title |
|---|---|
| Mr. Ian D. Page | CEO, MD & Exec. Director |
| Mr. Paul Nicholas Sandland MAAT, FCCA | CFO & Exec. Director |
| Dr. Anthony Gerard Griffin | MD of Dechra Veterinary Products for Europe & Exec. Director |
| Mr. Patrick Meeus | Group Scientific Officer |
| Ms. Katy Clough | Group HR Director |
| Mr. Mike Eldred | Pres of North America |
| Ms. Melanie Hall | Company Sec. |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 23.8095 |
|---|---|
| Trailing PE: | 50.9057 |
| Price-to-Book MRQ: | 4.8138 |
| Price-to-Sales TTM: | 4.6311 |
| IPO Date: | 2000-09-21 |
| Fiscal Year End: | June |
| Full Time Employees: | 1998 |